Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (41-50 of 787) with videos related to

Pageof 79
Sort By:
Revue Medicale De Liege|April 19, 2019
[Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME]A J Scheen
Revue Medicale De Liege|November 19, 2020
[SARS-CoV-2 and COVID-19: not at the end of doubts, questions and controversies]A J Scheen
Revue Medicale De Liege|March 24, 2015
[How I treat...The choice between a sulphonylulrea and a gliptin to manage hyperglycaemia in type 2 diabetes]A J Scheen
Revue Medicale De Liege|March 24, 2015
[Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes]A J Scheen
Diabetes & Metabolism|August 5, 2020
Metformin and COVID-19: From cellular mechanisms to reduced mortalityA J Scheen
Revue Medicale De Liege|June 23, 2006
[How I explore...outcomes in clinical trials: comments about recent studies of cardiovascular prevention]A J Scheen
Revue Medicale De Liege|March 9, 2007
[The Liège Medical Journal at the crossroads]A J Scheen
Revue Medicale De Liege|August 30, 2007
[The added value of therapy]A J Scheen
Revue Medicale De Liege|December 31, 2008
[Drug selection guided by known and newly diagnosed comorbidities in a multi-risk patient]A J Scheen
Revue Medicale De Liege|July 1, 1991
[Current therapeutic agents 1989-1990]A J Scheen
Pageof 79

Showing results (41-50 of 787) with videos related to

Sort By:
Pageof 79
Revue Medicale De Liege|April 19, 2019
[Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME]A J Scheen
Revue Medicale De Liege|November 19, 2020
[SARS-CoV-2 and COVID-19: not at the end of doubts, questions and controversies]A J Scheen
Revue Medicale De Liege|March 24, 2015
[How I treat...The choice between a sulphonylulrea and a gliptin to manage hyperglycaemia in type 2 diabetes]A J Scheen
Revue Medicale De Liege|March 24, 2015
[Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes]A J Scheen
Diabetes & Metabolism|August 5, 2020
Metformin and COVID-19: From cellular mechanisms to reduced mortalityA J Scheen
Revue Medicale De Liege|June 23, 2006
[How I explore...outcomes in clinical trials: comments about recent studies of cardiovascular prevention]A J Scheen
Revue Medicale De Liege|March 9, 2007
[The Liège Medical Journal at the crossroads]A J Scheen
Revue Medicale De Liege|August 30, 2007
[The added value of therapy]A J Scheen
Revue Medicale De Liege|December 31, 2008
[Drug selection guided by known and newly diagnosed comorbidities in a multi-risk patient]A J Scheen
Revue Medicale De Liege|July 1, 1991
[Current therapeutic agents 1989-1990]A J Scheen
Pageof 79